# Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference
Ticker: MLYS
Company: Mineralys Therapeutics
Source: Mineralys Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.mineralystx.com
## Summary

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on…...

## Article Body
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.

Goldman Sachs 47th Annual Global Healthcare Conference Date: Tuesday, June 9, 2026 Time: 2:40pm ET Format: Fireside Chat Webcast Link A live webcast of this fireside chat can also be accessed on the “ News & Events ” page in the Investors section of the Mineralys Therapeutics website.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn , Twitter and Bluesky .

Contact:

Investor Relations investorrelations@mineralystx.com

Media Relations Melyssa Weible Elixir Health Public Relations Email: mweible@elixirhealthpr.com

Source: Mineralys Therapeutics, Inc. Released June 8, 2026
## Recent Company News
- 2026-06-25 13:46 EST — [Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-and-heart-failure-risk-biomarkers-at-the-endocrine-society-annual-meeting-endo-2026) — Source: Mineralys Therapeutics
- 2026-06-25 13:46 EST — [Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Mineralys Therapeutics
- 2026-06-25 13:46 EST — [Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-present-late-breaking-data-on-lorundrostat-at-the-endocrine-society-annual-meeting-endo-2026) — Source: Mineralys Therapeutics
- 2026-06-25 13:46 EST — [Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-pricing-of-150-million-underwritten-offering-of-common-stock) — Source: Mineralys Therapeutics
- 2026-06-25 13:46 EST — [Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-repurchase-of-royalty-obligations-in-tanabe-license-agreement-and-concurrent-financing) — Source: Mineralys Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)